Pulmonary Embolism Market Set to Expand to US$3.5 Billion by 2031, Driven by 8.1% CAGR, Says Persistence Market Research

The global pulmonary embolism (PE) market is on a steep growth trajectory, primarily driven by an increasing prevalence of risk factors and advances in diagnostic and treatment technologies. Pulmonary embolism is a serious condition that occurs when a blood clot, often originating from the legs (deep vein thrombosis), travels to the lungs, causing a blockage. This can lead to severe complications or even death if left untreated. The market for pulmonary embolism is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2024 to 2031, with the global market revenue projected to increase from US$1.5 billion in 2024 to US$3.5 billion by 2031.

Key growth drivers behind this market include the aging population, the rising number of cancer patients, and the increasing use of telemedicine. As healthcare systems evolve and the demand for effective treatments grows, pulmonary embolism treatment is seeing significant advancements. Diagnostic tools such as CT pulmonary angiography (CTPA) are becoming the gold standard due to their accuracy and speed in detecting blood clots in the lungs, driving growth in the diagnostic segment. Furthermore, an increase in healthcare budgets worldwide is fueling investments in PE diagnostics and treatment infrastructure.

Among the various treatment options available for PE, medications, particularly anticoagulants (blood thinners), dominate the market, providing effective management of the condition. Hospitals remain the leading end-user segment due to the complex nature of PE management, requiring advanced facilities and skilled professionals. Geographically, North America leads the market in terms of revenue, largely owing to the presence of key industry players, robust healthcare infrastructure, and a high prevalence of chronic diseases that increase the risk of PE.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response):
https://www.persistencemarketresearch.com/samples/34496

✅ Key Highlights from the Report

➤ The global pulmonary embolism market is projected to reach US$3.5 billion by 2031.
➤ North America is the largest revenue-generating region for the market.
➤ The growing prevalence of cancer, particularly among elderly patients, is boosting market demand.
➤ Medications such as blood thinners (anticoagulants) dominate the treatment segment.
➤ Advances in diagnostic tools, such as CT pulmonary angiography, are enhancing diagnosis accuracy.
➤ Telemedicine adoption is on the rise, allowing remote monitoring of PE patients.

✅ Market Segmentation

The global pulmonary embolism market is segmented based on product type, treatment approach, end-user, and region. The most prominent segmentation is by symptom, diagnosis, treatment, and end-user.

In terms of treatment, medications remain the dominant segment, with anticoagulants playing a crucial role in preventing further clot formation and promoting the breakdown of existing clots. These medications are widely used due to their efficacy and low invasiveness, making them suitable for both acute and chronic PE cases. Additionally, mechanical devices, such as thrombectomy devices, are gaining traction for more severe cases of PE, where clot removal is necessary.

When it comes to diagnosis, CT pulmonary angiography (CTPA) has emerged as the gold standard. CTPA is known for its high accuracy and speed, providing detailed images of blood vessels in the lungs. Other diagnostic methods, including MRI, chest X-rays, and D-Dimer tests, are also employed, depending on the patient's condition and risk factors. The growing demand for minimally invasive diagnostic tools is further pushing the market for advanced imaging technologies.

Hospitals continue to be the primary end-user segment due to their ability to offer specialized care, advanced diagnostic tools, and the expertise required for treating complex cases of pulmonary embolism. Hospitals are also the main distribution channel for PE treatments, with hospital pharmacies stocking the necessary medications and devices.

✅ Regional Insights

The North American market for pulmonary embolism treatment leads globally, primarily due to the high prevalence of chronic diseases such as cancer and cardiovascular disorders. North America's healthcare system is one of the most advanced in the world, with widespread access to state-of-the-art diagnostic tools like CT pulmonary angiography, making the region a hotspot for pulmonary embolism diagnosis and treatment. Additionally, the region's aging population and rising obesity rates contribute to the increasing number of PE cases, further driving market demand.

Europe follows closely, benefiting from robust healthcare infrastructure and government investments in health services. The demand for innovative PE treatment options, particularly for the elderly population, is expected to drive substantial growth in this region. The presence of leading pharmaceutical companies and ongoing research in PE diagnostics and treatments are key factors contributing to the regional market's growth.

✅ Market Drivers

The pulmonary embolism market is significantly driven by the ascendant prevalence of cancers worldwide. According to the World Health Organization, cancer is a leading cause of death globally, and patients undergoing chemotherapy are at an elevated risk of developing pulmonary embolism. This, in turn, is propelling the demand for effective PE medications and treatment options.

Another key market driver is the investment in healthcare infrastructure. Governments and private entities are increasingly investing in healthcare, leading to better access to advanced diagnostic tools and treatment facilities. This influx of capital has translated into better detection rates and faster, more efficient treatment protocols for pulmonary embolism, which is accelerating market growth.

✅ Market Restraints

Despite its growth prospects, the pulmonary embolism market faces several challenges. A major restraint is the lack of awareness regarding PE symptoms, causes, and treatment options. Many people, including healthcare professionals, fail to recognize the symptoms early, leading to delayed diagnosis and treatment, which could worsen patient outcomes. Additionally, high treatment costs associated with PE management, particularly advanced procedures like thrombectomy or catheter-directed thrombolysis, can strain healthcare systems and deter patients from seeking timely care.

✅ Market Opportunities

The rising R&D activity focused on pulmonary embolism presents a lucrative opportunity for market growth. With pharmaceutical companies and research institutions working on new drugs, improved diagnostic methods, and innovative treatment technologies, the market is expected to witness significant breakthroughs. Moreover, the approval of next-generation PE treatments with better efficacy and fewer side effects will create new opportunities for market players. As more drug approvals and medical device innovations hit the market, the pulmonary embolism treatment landscape will evolve, providing ample growth prospects.

✅ Frequently Asked Questions

➤ How big is the pulmonary embolism market?
➤ Who are the key players in the global pulmonary embolism market?
➤ What is the projected growth rate of the pulmonary embolism market?
➤ What is the market forecast for pulmonary embolism treatment by 2032?
➤ Which region is estimated to dominate the pulmonary embolism industry through the forecast period?

✅ Company Insights

The pulmonary embolism market is home to several key players that are pivotal in advancing treatments and diagnostic methods for PE. Some of the leading companies operating in the market include:

✦ Bayer AG
✦ Johnson & Johnson
✦ Boehringer Ingelheim
✦ Pfizer Inc.
✦ Bristol-Myers Squibb
✦ Amgen Inc.
✦ AbbVie Inc.
✦ Anthos Therapeutics
✦ Astellas Pharma Inc.
✦ Argenx SE
✦ Daiichi Sankyo Co. Ltd.
✦ F. Hoffmann La Roche Ltd.
✦ Eli Lilly and Co.
✦ Gilead Sciences Inc.
✦ Medtronic Plc
✦ Inari Medical Inc.
✦ Novartis AG
✦ Sanofi
✦ Viatris Inc.
✦ Takeda Pharmaceutical Co. Ltd.

✅ Recent Developments

■ May 2024: AngioDynamics confirmed the safety and effectiveness of its AlphaVac device for treating acute pulmonary embolism. The device significantly improved heart function and reduced clot burden during trials, positioning it as a promising tool for PE treatment.

■ May 2024: A new radiology procedure for treating pulmonary thromboembolism was introduced at BMHRC. The technique, involving catheter-directed thrombolysis (CDT), represents a less invasive alternative to traditional treatment methods, promising quicker recovery times and reduced complications.

Conclusion

The pulmonary embolism market is poised for substantial growth, with innovations in diagnostic techniques, drug therapies, and minimally invasive treatment options driving market expansion. Factors such as the increasing prevalence of cancer, chronic diseases, and an aging population are expected to continue fueling demand for effective PE management solutions. However, the market faces challenges such as limited awareness and high treatment costs, which could hinder growth in certain regions. Nonetheless, ongoing research and advancements in the field offer significant opportunities, making it an exciting space for market players and investors alike.

Contact Us:
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.